Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Swedish Medical Center
With
GlaxoSmithKline
The MTD was found in the phase I portion of this study to be oral lapatinib 1000 mg per day for each 4 week cycle and paclitaxel 60 mg/m2 weekly x 3 of a 4 week cycle and carboplatin AUC 2 weekly x 3 of a 4 week cycle.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Relapsed (Stage III or IV) ovarian, primary peritoneal, fallopian tube carcinoma patients.
Stage IV metastatic breast cancer patients who have failed no more than four previous chemotherapies for Stage IV disease.
Ability to swallow and retain oral medications.
Measurable disease
You may not be if
Treatment with previous weekly carboplatin and paclitaxel.
No prior treatment with erbB targeting therapies such as erlotinib, gefitinib and cetuximab.
No concomitant requirement for medication classification as CYP3A4 inducers or inhibitors.
Clareo Health | Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients
